Victoria Richon (Ribon Therapeutics)

Ri­bon Ther­a­peu­tics is look­ing to break the mold for PARP in­hibitors and has a slate of Big Phar­ma back­ers on board

Ri­bon Ther­a­peu­tics broke three years of ra­dio si­lence back in ear­ly 2019 to spread the word of its $65 mil­lion Se­ries B round. Now, two and a half years lat­er, the com­pa­ny’s lead PARP in­hibitor has in­vestors reach­ing a lit­tle deep­er in­to their pock­ets.

CEO Vic­to­ria Ri­chon un­veiled a $65 mil­lion Se­ries B1 round on Wednes­day, which she de­scribed as an ex­ten­sion of the B round closed at the end of 2018. The lat­est round, led by Deer­field Man­age­ment and US Ven­ture Part­ners, brings the Cam­bridge, MA-based biotech’s to­tal raise up to about $175 mil­lion. A slate of Big Phar­ma play­ers al­so chipped in, in­clud­ing Ab­b­Vie Ven­tures, Bris­tol My­ers Squibb, John­son & John­son In­no­va­tion, Take­da Ven­tures and the No­var­tis Ven­ture Fund.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.